GlassScriptPhysician profile
Irina Kogan
NPI 1679730477
$14,353.89
in general payments reported to CMS, 2019-2025
50 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $1,482 · 2021: $2,909 · 2022: $2,730 · 2023: $2,847 · 2024: $1,783 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,952 · Education: $85.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,951.89 |
| Education | $85.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.93 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,653.48 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,153.96 | 2020-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $1,029.37 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Pfizer INC. | $825.58 | 2023-2025 | |
| Eisai INC. | $771.87 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $712.44 | 2020-2025 | Ztlido |
| Sk Life Science, INC. | $620.08 | 2020-2022 | |
| Alkermes, INC. | $603.74 | 2019-2025 | Aristada, Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $507.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $427.94 | 2020-2021 | |
| Amgen INC. | $397.00 | 2019-2023 | Aimovig |
| Ucb, INC. | $396.62 | 2019-2024 | Nayzilam, Briviact |
| Allergan, INC. | $375.25 | 2020-2021 | |
| Lilly USA, LLC | $348.96 | 2019-2024 | Emgality, Reyvow |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.